Foamix于2003年1月19号在以色列成立。该公司是一家临床阶段制药公司专注于开发和商业化公司专有的泡沫米诺环素治疗痤疮,脓疱疮等皮肤状况。该公司的主导候选产品,fmx101为中度至重...查看全文
牛唐2018-07-28 22:07
$Foamix(FOMX)$ FMX101是外用的minocyline,用于治疗痤疮,预计今年下半年或明年上半年申报NDA,如果获批的话,将是首个获批的米诺环素外用药查看全文
$Foamix(FOMX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001193125-20-008980 Act: 34 Size: 22 KB 网页链接
$Foamix(FOMX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001193125-20-008059 Act: 34 Size: 28 KB 网页链接
$Foamix(FOMX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-20-007160 Act: 34 Size: 97 KB 网页链接
$Foamix(FOMX)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001104659-20-003639 Act: 34 Size: 78 KB 网页链接
$Foamix(FOMX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001104659-20-003101 Act: 34 Size: 2 MB 网页链接
$Foamix(FOMX)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-20-005447 Act: 34 Size: 27 KB 网页链接
$Foamix(FOMX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-002722 Act: 34 Size: 64 KB 网页链接
$Foamix(FOMX)$ DEFM14A Definitive proxy statement relating to merger or acquisition Accession Number: 0001193125-20-003085 Act: 34 Size: 3 MB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-001250 Size: 4 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-001237 Size: 4 KB 网页链接